Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Steroid for Refractory Anterior Cutaneous Nerve Entrapment Syndrome (ACNES)
jRCTs061240098Active, not recruiting
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of methylprednisolone sodium succinate in Abdominal Cutaneous Nerve Entrapment Syndrome (ACNES). Primary endpoint: Safety of Solu-Medrol administration. Started Mar 2025; status: active, not recruiting.
02
Drugs
methylprednisolone sodium succinate
03
Conditions
Abdominal Cutaneous Nerve Entrapment Syndrome (ACNES)
Beyond the preview
Go deeper on jRCTs061240098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240098.